CBP 174
Alternative Names: CBP-174Latest Information Update: 28 Jun 2024
At a glance
- Originator Arena Pharmaceuticals
- Developer Suzhou Connect Biopharmaceuticals
- Class Anti-inflammatories; Antipruritics; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pruritus
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Pruritus(In volunteers) in Australia (PO, Liquid)
- 30 Aug 2022 Adverse events and Pharmacokinetic data from a phase I trial in pruritus was released by Connect Biopharma
- 17 May 2022 Suzhou Connect Biopharmaceuticals completes a phase-I clinical trial in Pruritus (In volunteers) in Australia (PO, Liquid) (NCT04811469)